13 In 1993, The Journal of Clinical Apheresis published a paper detailing the use of TPE as either a first- or second-line therapy to be used with other modalities on disorders such as Raynauds disease, systemic lupus erythematosus, coagulation factor inhibitors, familial hypercholesterolemia, acute Guillain-Barr syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, cryoglobulinemia, Goodpastures syndrome, and thrombotic thrombocytopenic purpura
We suggest obtaining bacteriostatic water and related items from this premier research materials supplier
Agonistas del GLP-1 en el manejo de la diabetes tipo 2 El manejo de la diabetes tipo 2 suele ser complejo e implica cambios en el estilo de vida, el control de la glucemia y la medicacin
Everything here is informed speculation for planning purposes
Ravanidis S, Bougea A, Papagiannakis N et al (2020) Validation of differentially expressed brain-enriched microRNAs in the plasma of PD patients